SCHEMBL6036731

SCHEMBL6036731

CCNC1CNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7013899 0.97 — —
SCHEMBL1996565 0.84 KCNH2 (0.50) —
SCHEMBL1994453 0.82 KCNH2 (0.48) —
SCHEMBL1781000 0.79 — —
SCHEMBL2012943 0.79 — —
SCHEMBL1782773 0.79 — —
SCHEMBL23970735 0.79 KCNH2 (0.50) —
SCHEMBL24850090 0.79 KCNH2 (0.50) —
SCHEMBL17778122 0.79 KCNH2 (0.50) —
SCHEMBL4661086 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073371-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
CN-116848091-A Inhibitors of ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP 1) and uses thereof 1CBIO公司 2023-10-03 — — CN disclosed
WO-2023109892-A1 COMPOUND FOR INHIBITING OR DEGRADING BRD9, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF 海思科医药集团股份有限公司 2023-06-22 — — WO disclosed
US-20230167094-A1 H4 ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2023-06-01 — — US disclosed
EP-4105203-A1 SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS Epizyme Inc (US) 2022-12-21 — — EP disclosed
EP-3519393-B1 SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS EPIZYME INC (US) 2022-05-18 — — EP disclosed
EP-3784666-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-03-16 — — EP disclosed
WO-2021027943-A1 PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF 正大天晴药业集团南京顺欣制药有限公司 2021-02-18 — — WO disclosed
WO-2019148150-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-08-01 — — WO disclosed
EP-3473616-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2019-04-24 — — EP disclosed
WO-2011054845-A1 BENZODIAZEPINE BROMODOMAIN INHIBITOR GLAXOSMITHKLINE LLC (US) 2011-05-12 — — WO disclosed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 — — US disclosed
EP-1680429-A1 THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS Celltech R &amp; D Limited (GB) 2006-07-19 — — EP disclosed
WO-2005042540-A1 THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2005-05-12 — — WO disclosed
US-6858625-B1 Quinolinecarboxylic acid derivative or salts thereof WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2005-02-22 — — US disclosed
CN-1157389-C Quinoline carboxylic acid derivative or salt thereof ������ҩ��ʽ���� 2004-07-14 — — CN disclosed
EP-1193266-B1 QUINOLINECARBOXYLIC ACID DERIVATIVE OR SALTS THEREOF WAKUNAGA PHARMA CO LTD (JP) 2003-08-27 — — EP disclosed
CN-1358183-A Quinolinecarboxylic acid derivative or salts thereof WAKUZAGA PHARMACEUTICAL CO LTD (JP) 2002-07-10 — — CN disclosed
EP-1193266-A1 QUINOLINECARBOXYLIC ACID DERIVATIVE OR SALTS THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2002-04-03 — — EP disclosed
WO-1993007144-A1 1,8-BENZONAPHTHYRIDINE DERIVATIVES AND ANTIMICROBIAL COMPOSITIONS LABORATOIRE ROGER BELLON (FR) 1993-04-15 — — WO disclosed
Send feedback